Avacta Group plc, a life sciences company that develops targeted oncology drugs and diagnostics, has dosed the first patient in the US as part of its phase 1 multi-center trial
Avacta Group PLC (AIM:AVCT) Preliminary Results for the year ended 31 December 2022
A period of continued significant progress
Avacta Group PLC (AIM:AVCT) AVA3996 data poster presented at AACR
Avacta Presents AVA3996 Pre-clinical Data at the American Association for Cancer Research Meeting
Avacta shares: brief update for Q2 2023
Avacta has expanded its footprint in the US. The listing could be next.
Avacta Opens First Two US Clinical Investigator Sites for AVA6000 Phase 1 Clinical Study
Memorial Sloan Kettering Cancer Center and Fred Hutch Cancer Center are now open for patient enrolment to pre|CISION™ lead programme, AVA6000
Avacta Group PLC (AIM:AVCT) First Patient Dosed in Fifth Cohort of AVA6000
First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study
Abingdon Health PLC (AIM:ABDX) Senzo and Abingdon Health enter into strategic partnership
Abingdon Health’s CDMO service to support Senzo in leveraging its innovative, high-accuracy Amplified Lateral Flow (ALF) point-of-care diagnostics platform technology across multiple product opportunities
Abingdon Health PLC (AIM:ABDX) AppDx ® lateral flow smartphone reader granted further patent
York, U.K. 7 March 2023: Abingdon Health plc (AIM: ABDX), a leading international lateral flow contract development and manufacturing organisation (CDMO), announces the granting of an additional patent for its
Abingdon Health PLC (AIM:ABDX) Trading Update
York, U.K. 28 February 2023: Abingdon Health plc (AIM: ABDX), a leading international lateral flow contract development and manufacturing organisation (CDMO), provides its half-year trading update for the six months
Avacta Group PLC (AIM:AVCT) Avacta Therapeutics Division Science Day
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, is today holding a Science Day, focused on its Therapeutics Division, for institutional
Avacta Group PLC (AIM:AVCT) Successful Completion of Fourth Dose Escalation
Avacta Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study